GET DAILY SIGNALSWhy Is Replimune Group (REPL) Stock Down -3.76% Today?
Key Takeaways
- REPL shares fell 3.76% to roughly $20.96, extending a pullback from a recent 52-week high near $23.41.
- The decline reflects profit-taking after a sharp, months-long rally rather than fresh negative company news.
- Insider selling—including recent director stock sales disclosed in SEC filings—has weighed on sentiment.
- Elevated short interest near 36% of the float is amplifying intraday swings in both directions.
- Broader small-cap biotechnology names are trading mixed, providing little sector support to offset the profit-taking.
- Traders are watching whether the stock holds technical support after its overbought run and how early TUDRIQEV launch momentum develops.
- For additional details, explore Replimune's Price Targets, Earnings, and Forecast pages.
- For AI-driven trading ideas across thousands of tickers, visit Trending AI Robots.
Opening Summary
Replimune Group, Inc. (REPL) is a Woburn, Massachusetts-based clinical-stage biotechnology company developing oncolytic immunotherapies built on an engineered herpes simplex virus backbone. Its lead product, RP1 (vusolimogene oderparepvec), marketed as TUDRIQEV, received accelerated FDA approval in August 2026 for advanced melanoma in combination with nivolumab and launched commercially in October 2026. In today's session, the stock fell 3.76% to approximately $20.96, down from a prior close of $21.78, as investors continued to lock in gains following one of the sector's most dramatic rallies of the year.
Profit-Taking After a Parabolic Rally
The primary driver behind the decline appears to be sustained profit-taking. REPL has been among the strongest small-cap biotech performers in recent months, climbing roughly 67% over the past month and more than 120% year-to-date as the regulatory outlook shifted from repeated FDA setbacks to commercial launch. After touching a 52-week high near $23.41, the shares have now pulled back for consecutive sessions—a pattern consistent with investors monetizing outsized gains rather than reacting to a new fundamental event.
Insider Selling Weighs on Sentiment
Recent insider transactions have added to the selling pressure. SEC Form 4 filings show that a company director sold shares in early November at prices near the stock's recent highs, part of a broader string of insider sales disclosed over the past several weeks. While insider selling can occur for personal financial-planning reasons unrelated to company fundamentals, in a thinly covered, momentum-driven name such disclosures often dampen retail and institutional enthusiasm in the near term.
Elevated Short Interest and Technical Conditions
Technical conditions also contributed to the pullback. With the 14-day relative strength index (RSI) running well into overbought territory above 70 during the rally, the shares were vulnerable to a mean-reversion move. Short interest near 36% of the float remains a key variable, amplifying volatility in both directions; any meaningful bid can trigger sharp short-covering rallies, while periods of profit-taking can accelerate downside moves as momentum traders exit. Today's decline, while notable, is modest relative to the stock's recent gains.
Market Context and Trading Activity
Trading volume has remained elevated relative to the stock's recent averages, reflecting active repositioning after the late-October earnings report and the TUDRIQEV launch update. The move is largely company-specific rather than a broad biotech sell-off: small-cap healthcare names are trading mixed, and major equity indices have not moved sharply lower, underscoring that today's action in REPL is being driven by stock-specific positioning and profit-taking dynamics.
What Comes Next for REPL
Looking ahead, investors will focus on the trajectory of the TUDRIQEV commercial launch, including formulary access, prescribing accounts, and early patient-treatment metrics, which management detailed in its fiscal second-quarter update. The company ended the quarter with roughly $308 million in cash and has indicated a runway extending beyond twelve months. Key considerations include the pace of revenue recognition from the newly launched therapy, progress across the broader RP1 and RP2 pipeline, and whether elevated short interest triggers further volatility. Risks include execution of the commercial launch, ongoing securities litigation related to prior regulatory disclosures, and the inherent uncertainty of clinical-stage drug development.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of AI-powered trading bots that have demonstrated strong performance under current market conditions. Tickeron offers hundreds of these automated trading bots covering thousands of tickers, with each bot varying by strategy, timeframe, performance metrics, and the symbols it trades. Only the strongest performers are featured in this curated section, providing traders with a focused view of strategies that are currently working. Explore the Trending AI Robots page to discover tools that may help you navigate volatile markets.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
REPL's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for REPL turned positive on October 26, 2026. Looking at past instances where REPL's MACD turned positive, the stock continued to rise in 43 of 49 cases over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on REPL as a result. In 65 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
REPL moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for REPL crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +7.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where REPL advanced for three days, in 183 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
REPL broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for REPL entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. REPL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.282) is normal, around the industry mean (3.498). P/E Ratio (-6.863) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REPL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of oncolytic immunotherapies
Industry Biotechnology
Advertisement